- Home
- APLT vs VWAV Comparison
APLT vs VWAV Comparison
Compare APLT & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- VWAV
- Stock Information
- Founded
- APLT 2016
- VWAV 2024
- Country
- APLT United States
- VWAV United States
- Employees
- APLT N/A
- VWAV N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- VWAV Computer Software: Prepackaged Software
- Sector
- APLT Health Care
- VWAV Technology
- Exchange
- APLT Nasdaq
- VWAV Nasdaq
- Market Cap
- APLT 178.6M
- VWAV 162.2M
- IPO Year
- APLT 2019
- VWAV N/A
- Fundamental
- Price
- APLT $0.26
- VWAV $9.89
- Analyst Decision
- APLT Buy
- VWAV
- Analyst Count
- APLT 5
- VWAV 0
- Target Price
- APLT $4.13
- VWAV N/A
- AVG Volume (30 Days)
- APLT 24.7M
- VWAV 294.5K
- Earning Date
- APLT 11-13-2025
- VWAV 11-19-2025
- Dividend Yield
- APLT N/A
- VWAV N/A
- EPS Growth
- APLT N/A
- VWAV N/A
- EPS
- APLT N/A
- VWAV N/A
- Revenue
- APLT $1,000,000.00
- VWAV N/A
- Revenue This Year
- APLT N/A
- VWAV N/A
- Revenue Next Year
- APLT $5,935.35
- VWAV N/A
- P/E Ratio
- APLT N/A
- VWAV N/A
- Revenue Growth
- APLT N/A
- VWAV N/A
- 52 Week Low
- APLT $0.22
- VWAV $2.06
- 52 Week High
- APLT $10.48
- VWAV $18.41
- Technical
- Relative Strength Index (RSI)
- APLT 27.74
- VWAV N/A
- Support Level
- APLT $0.26
- VWAV N/A
- Resistance Level
- APLT $0.40
- VWAV N/A
- Average True Range (ATR)
- APLT 0.12
- VWAV 0.00
- MACD
- APLT -0.07
- VWAV 0.00
- Stochastic Oscillator
- APLT 4.83
- VWAV 0.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About VWAV VisionWave Holdings Inc. Common Stock
VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.